Etomidate shortage — HR supply status & alternatives

Etomidate

ATC N01AX07

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US🌐 HR🌐 TW

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Etomidate
ATC level 5	N01AX07
ATC level 4	N01AX
Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper

Marketing-authorisation holders	B BRAUN MELSUNGEN AG, HIKMA PHARMACEUTICALS USA INC., HF Acquisition Co LLC, DBA HealthFirst, Eugia US LLC +2 more

Registrations on file	8

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

5 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk

Pisgah Labs INCBachem SAChemwerth INCSolara Active Pharma Sciences LTDGland Pharma LTD

Manufacturing countries: Switzerland, China, India · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

Etomidate Injection

Heritage Pharmaceuticals, Inc. · Feb 2019

Class IIdetails ↗

🇺🇸

Etomidate Active Pharmaceutical Ingredient Packaged In Varyi

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

🇺🇸

Etomidate Injection

Agila Specialties Private Ltd. · Feb 2014

Class IIdetails ↗

🇺🇸

Etomidate

Franck's Lab Inc., d.b.a. Franck's Compounding Lab · May 2012

Class IIdetails ↗

Verified timeline regulator events

🌐 3 July 2025

medium reported

🌐 5 July 2023

medium reported

🇺🇸 5 Oct 2022

medium reported

🇺🇸 5 Oct 2022

medium reported

🌐 5 Sept 2022

Shortage resolved

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders8 registrations · 6 MA holders

Product	Strength	Form	Market	MA holder	Status
ETOMIDATE 2 MG/ML EMULSION FOR INJECTION	2 MG	injection	🇬🇧 GB	B BRAUN MELSUNGEN AG	Active
Etomidate	2mg/mL	injection	🇺🇸 US	HIKMA PHARMACEUTICALS USA INC.	Active
Amidate Etomidate	2mg/mL	injection	🇺🇸 US	HF Acquisition Co LLC, DBA HealthFirst	Active
ETOMIDATE	40mg/20mL	injection	🇺🇸 US	HF Acquisition Co LLC, DBA HealthFirst	Active
ETOMIDATE injection, solution	20mg/10mL	injection	🇺🇸 US	HF Acquisition Co LLC, DBA HealthFirst	Active
ETOMIDATE	20mg/10mL	injection	🇺🇸 US	Eugia US LLC	Active
Etomidate Injection Usp	—	solution	🇨🇦 CA	MARCAN PHARMACEUTICALS INC	Active
Etomidate Injection, Usp	—	solution	🇨🇦 CA	FRESENIUS KABI CANADA LTD	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.